Tyler is responsible for product development, manufacturing, production, quality control, quality assurance, and customer satisfaction at Psilly and Ei Ventures. Tyler is also the Founder of G. Randall & Sons, Inc, where he created Randy's Remedy: a scientifically formulated topical cream optimized for the delivery of natural cannabinoids.
Tyler gained experience and knowledge of advanced botanical extraction and analytical techniques alongside Ph.D. analytical and physical chemists. He conducted extensive research about the antitumor effects of cannabinoids and became a subject matter expert. In 2012 Tyler founded Randy’s Club, a California non-profit serving the needs of qualified patients participating in the California State Medical Marijuana Program.
Tyler served as a board member of a local non-profit. He worked with local elected officials, patients, and community stakeholders to build a broad consensus around the principles of safe, affordable access to medical marijuana for qualified patients in San Diego and its surrounding communities. In addition, he was the manager at the first legally licensed dispensary in San Diego county, participating in start-up activities, ensuring compliance with regulations, and serving qualified customers.
Tyler also worked at UC Davis Cancer Center’s regulatory affairs office, San Diego Hospice Education and Research Department, and Aspire, an independent Institutional Review Board. He graduated with a degree in Philosophy from the University of California at Davis.
For more information: https://invest.ei.ventures/
Ei.Venture in partnership with their portfolio company Psilly is hosting a webcast to help raise awareness of alternative approaches to treating mental health disorders like anxiety and depression. According to a study by John Hopkins Medicine, over 9.5% of adult Americans suffer from depression. Fortune Business Insights says that the global market size for anxiety disorders and depression treatment was USD $8.50 billion in 2019 and is projected to reach USD $13.03 billion by 2027. Additionally, over 18% of Americans suffer from anxiety disorders and up to 40% of Americans say they are more anxious in 2022 than last year. A good sign is that this number is down from 63% of those surveys since the spike up in 2021.
Why are modern day psychiatric drugs missing the market and how a group of entrepreneurs, researchers and scientists aim to fix it?
How ancient plant wisdom combined with 21st Century science is changing the way the world views psilocybin as a credible treatment plan?
Psilly will also cover their plans to build treatment centers in the Metaverse. Web 3.0 is a decentralized and fair internet where users control their own data, identity and destiny. Web 3.0 has enormous potential for growth over the next 25 years. The Psilly team has 144 lots of land in Sandbox that are in a prime location. In real estate, you have heard the term location, location, location. Well, the firm has digital real estate that is located right next door to the largest online play to earn decentralized video game company. The presentation will also include an overview of the Psilly thinking and plans. Having a view is great, having a view with an orthogonal expression is even better.
For more information: https://invest.ei.ventures/
Speakers: David Nikzad, Cecil Robles, Linda G Strause, PH.D., and Tyler Strause
More people than ever are struggling with mental health. As a society, we don’t currently have adequate mental health treatment that targets the root problem without hefty costs (reliance on daily medication, side effects, potential substance abuse). Big Pharma has failed to address the problem and the world wants a different solution.
Psilocybin and functional mushrooms allow us to rewire our neural pathways and naturally address what we typically try to control via medication. Psilly, brought to you by E.I. Ventures, is changing the narrative around psychedelic therapy so that plant-powered mushrooms can move through FDA trials and provide people a safer and more efficient path to self-improvement.
Psilly provides a path to what’s growing all around us: a “gold standard” of plant-powered, psychedelic therapy. Rather than compete over ownership of a natural compound, Psilly offers a delivery system, therapeutic framework, educational platform, and community that will ensure that people experience the value that psychedelic mushrooms have to offer for as accessible a cost as possible - $1 per dose.
We are focused on three key areas in order to scale psychedelic therapy and mental health and wellness options to the millions currently suffering:
1. Botanical pharmaceutical ingredients
2. Drug delivery mechanisms
3. Web3 psychedelic therapy and technology
Invest in Psilly, brought to you by E.I. Ventures, to bring 100% plant-based therapies through FDA trials to help 1 billion people for $1 each.
Learn more at invest.ei.ventures
We started our journey over 12 years ago in Los Angeles, bringing healing modalities to a growing community of individuals curious about alternative paths to health and wellness. Then came the island of Maui, Hawaii, where we connected with farmers, chemists, and iconic leaders of psychedelic medicine to explore the power of the plant and natural therapies that unlock the mind and heal the soul. Psilly, a continuation of Orthogonal Thinker and E.I. Ventures's mission of conscious, sustainable investing and community building, was born in 2021.
Our team consists of experts, teachers, and healers from across innovative corners of psychedelic medicine, cannabis, CBD, academia, and physical healing spaces. Working and living across Miami, Maui, and Northern California, we all share a common respect for natural medicine and what's possible when you reimagine the strategy of pharmaceuticals to present people with a new path to self-improvement.